Product logins

Find logins to all Clarivate products below.


Disease Intelligence & Analytics

Expert curated disease intelligence and analytics to size disease markets, guide strategy, and stay ahead of clinical and competitive shifts.

Expert curated disease intelligence solutions for every disease market

DRG Disease Intelligence & Analytics delivers end to end disease intelligence by bringing together epidemiology driven population insights and expert curated market understanding. This disease analytics platform helps life sciences teams size opportunities, understand disease evolution, and guide confident clinical and commercial strategy.

The advantages of a smarter strategy with disease analytics

Make confident decisions with a clear view of patient opportunity

Understand the true size, structure, and evolution of patient populations so you can ground decisions in a reliable view of disease dynamics. With a clear foundation of disease intelligence, teams can align on assumptions, strengthen planning, and make more confident strategic choices across the lifecycle.

Know every disease market

Gain a comprehensive, expert‑curated view of patient populations, treatment pathways, competitive dynamics, and epidemiology—so your teams always understand the full story behind every disease.

Identify opportunities before your competitors do

Spot emerging therapies, biosimilar‑driven shifts, unmet needs, and evolving standards of care early—helping you size markets, prioritize indications, and position assets for maximum impact.

Move faster with expert‑curated intelligence

Skip time‑consuming manual research. Disease Intelligence & Analytics distils complex disease landscapes into clear, actionable insights—accelerating onboarding, scenario planning, and strategic direction for cross‑functional teams.

Comprehensive disease intelligence across every indication and opportunity

Disease Intelligence & Analytics integrates epidemiology driven population insights and expert curated market analysis to support confident disease level decision making across the product lifecycle. Each intelligence suite is purpose built to answer different disease level questions—together forming a complete disease analytics foundation.

track_changes

DRG Market Assessment

Expert‑authored disease insights that integrate treatment pathways, unmet needs, competitive landscapes, physician and payer perspectives and indication‑level 10-year market forecasts—supporting strategic decisions across the product lifecycle.

edit

DRG Epidemiology Intelligence

Gold‑standard epidemiology built by a global team of epidemiologists and therapy‑area experts, delivering fast, reliable incidence and prevalence data, 10–20‑year forecasts, and granular segmentation across 1,000+ diseases, including rare and niche conditions.

Get expert disease insights with our disease analytics platform

Connect with our experts to unlock clearer disease insights through our disease intelligence solution.

Questions we help answer

These disease level intelligence questions define smarter portfolio, clinical, and commercial decision making.

  • How large are the patient and sub‑population segments, and how will they evolve over time?
  • How are treatment patterns, standards of care, and competitive dynamics changing within this disease area – and what does this mean for market performance?
  • Where are the highest‑value market opportunities—and which indications or markets should we prioritize next?
  • How do we compare opportunities across disease areas to prioritize investment, resources, and portfolio strategy?

Why leading teams choose disease intelligence platform?

1000+
1000+indications and 300+ rare diseases covered
100+
expert therapy‑area specialists
40+
expert epidemiologists
85+
indications supported with 10-year market forecasts
240+
indications supported with 10–20-year epidemiology forecasts
30+ years
of epidemiology and disease‑market expertise

Resources

블록버스터 신약보고서 2026 Q&A: Lilly의 차세대 체중감량 치료제 블록버스터 신약보고서 2026 Q&A: Lilly의 차세대 체중감량 치료제
블로그 2026년 3월 26일
블록버스터 신약보고서 2026 Q&A: Lilly의 차세대 체중감량 치료제

최근 웨비나(“2026 년 블록버스터 신약보고서 웨비나: GLP-1 진화의 다음 물결 탐색“)에서 좋은 질문들이 많이 나왔는데요, 이번 블로그는 클래리베이트의 전문분석가인 Carles Recasens와 Shambhavi Shukla가 이에 대한 답변을 한 내용을 공유합니다. Retatrutide:…

Market Event Summary Hub Market Event Summary Hub
Market Event Summary Hub
Market Event Summaries provide data‑driven insights into key trends shaping the life sciences and healthcare markets.
척추성근위축증 역학에 대한 이해 척추성근위축증 역학에 대한 이해
블로그 2025년 12월 18일
척추성근위축증 역학에 대한 이해

척수성근위축증(Spinal Muscular Atrophy, SMA)은 척수 내 알파 운동신경세포가 점진적으로 손상되면서 근육 약화와 위축이 진행되는 희귀 유전 질환입니다. 본 블로그 글은 여러 지역에서 수집한 유병률 데이터를 바탕으로 수행한 광범위한 역학 분석을…

클래리베이트의 역학 데이터를 활용한 목표 시장 예측 클래리베이트의 역학 데이터를 활용한 목표 시장 예측
블로그 2025년 12월 8일
클래리베이트의 역학 데이터를 활용한 목표 시장 예측

의약품 연구 개발 또는 상업화 투자 여부를 판단하기 위해서는 목표 시장에 대한 심층적인 이해가 필수적입니다. 클래리베이트는 글로벌 인구 데이터를 기반으로 발생률, 유병률, 약물 치료 가능 환자 수에 대한 정교한 예측을…

여성 건강 분야에서 새로운 길을 연 7개 기업들 여성 건강 분야에서 새로운 길을 연 7개 기업들
블로그 2025년 11월 24일
여성 건강 분야에서 새로운 길을 연 7개 기업들

여성 건강: 오랜 기간 소외되었지만, 이제는 글로벌 투자 우선순위로 전 세계 인구의 절반을 여성이 차지함에도 불구하고, 여성 건강은 오랜 기간동안 충분한 관심과 연구 및 투자를 받지 못했습니다. 편두통, 자가면역질환, 정신질환처럼…

chevron_left
chevron_right

Frequently asked questions

Disease intelligence combines epidemiology, market understanding, and expert analysis to provide a comprehensive view of how a disease evolves, how large the opportunity is, and how clinical and commercial dynamics shape decision making across the product lifecycle.

Disease Intelligence & Analytics delivers expert‑curated intelligence across epidemiology, treatment pathways, competitive landscapes, unmet need, patient segmentation, and long‑range forecasts. It brings together the essential elements teams need to size markets, understand disease evolution, and guide strategic decisions across the product lifecycle.

Disease Intelligence & Analytics is built by a multidisciplinary team of epidemiologists, therapy‑area experts, pharmacists, and analysts who validate every assumption and data point. Unlike generic datasets or automated outputs, Disease Intelligence & Analytics offers transparent methodologies, rigorous modeling, and expert interpretation—ensuring insights are both credible and actionable.

Yes. Disease Intelligence & Analytics integrates patient population forecasts, treatment dynamics, competitive movement, unmet need, and emerging therapy trends—helping teams identify the most attractive indications, quantify opportunity size, and prioritize investments with confidence.

Disease Intelligence & Analytics is a platform that brings together patient, market, and disease-level insights to support strategic decision-making. DRG Epidemiology Intelligence focuses on patient population data and forecasts, while DRG Market Assessment provides insight into treatment dynamics and market evolution. Together, they form complementary components within the DI&A platform, delivering a connected view to help teams prioritize opportunities and make confident decisions.

Get the full story of a disease

Enhance your disease strategy today

Epidemiology Intelligence

신뢰할 수 있는 역학 인텔리전스를 통해 발생률, 유병률 및 장기 환자 집단 예측 데이터를 제공하여 보다 확신 있는 전략 수립과 의사결정을 지원합니다.

DRG Market Assessment

Access expert curated disease market assessment insights into treatment dynamics, unmet need, competitive shifts, and access factors to size opportunities and shape confident market strategy.